These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2126987)

  • 1. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.
    Garaci E; Mastino A; Pica F; Favalli C
    Cancer Immunol Immunother; 1990; 32(3):154-60. PubMed ID: 2126987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice.
    Mastino A; Favalli C; Grelli S; Rasi G; Pica F; Goldstein AL; Garaci E
    Int J Cancer; 1992 Feb; 50(3):493-9. PubMed ID: 1735618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.
    Garaci E; Pica F; Mastino A; Palamara AT; Belardelli F; Favalli C
    J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):7-17. PubMed ID: 8435433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of natural killer activity by thymosin alpha 1 and interferon.
    Favalli C; Jezzi T; Mastino A; Rinaldi-Garaci C; Riccardi C; Garaci E
    Cancer Immunol Immunother; 1985; 20(3):189-92. PubMed ID: 3851698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
    Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
    Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment with thymosin alpha 1 and interferon enhances NK activity in immunosuppressed tumor bearing mice.
    Pica F; Mastino A; Grelli S; Jezzi T; Favalli C
    J Chemother; 1989 Jul; 1(4 Suppl):1167-9. PubMed ID: 16312818
    [No Abstract]   [Full Text] [Related]  

  • 7. Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice.
    Favalli C; Mastino A; Jezzi T; Grelli S; Goldstein AL; Garaci E
    Int J Immunopharmacol; 1989; 11(5):443-50. PubMed ID: 2807622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between thymic hormones and other immunomodulatory agents.
    Mastino A; Favalli C; Grelli S; Garaci E
    Ann Ist Super Sanita; 1991; 27(1):51-6. PubMed ID: 1958028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL).
    Tentori L; Leonetti C; Lozupone F; Bonmassar E
    Cancer Immunol Immunother; 1995 Dec; 41(6):375-83. PubMed ID: 8635195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymosin alpha 1 potentiates interleukin 2-induced cytotoxic activity in mice.
    Mastino A; Favalli C; Grelli S; Innocenti F; Garaci E
    Cell Immunol; 1991 Mar; 133(1):196-205. PubMed ID: 1991327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced immune response and antitumor immunity with combinations of biological response modifiers.
    Garaci E; Mastino A; Favalli C
    Bull N Y Acad Med; 1989 Jan; 65(1):111-9. PubMed ID: 2481523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
    Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
    Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus.
    D'Agostini C; Palamara AT; Favalli C; Sivilia M; Febbraro G; Bue C; Garaci E
    Int J Immunopharmacol; 1996 Feb; 18(2):95-102. PubMed ID: 8799359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays.
    Umeda Y; Sakamoto A; Nakamura J; Ishitsuka H; Yagi Y
    Cancer Immunol Immunother; 1983; 15(2):78-83. PubMed ID: 6553515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice.
    Gorelik E
    Cancer Res; 1987 Feb; 47(3):809-15. PubMed ID: 3802083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
    Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
    Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early appearance and activation of natural killer cells in tumor-infiltrating lymphoid cells during tumor development.
    Kurosawa S; Matsuzaki G; Harada M; Ando T; Nomoto K
    Eur J Immunol; 1993 May; 23(5):1029-33. PubMed ID: 8477798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a.
    Garaci E; Lopez M; Bonsignore G; Della Giulia M; D'Aprile M; Favalli C; Rasi G; Santini S; Capomolla E; Vici P
    Eur J Cancer; 1995 Dec; 31A(13-14):2403-5. PubMed ID: 8652276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of mouse resistance to Candida albicans infection by thymosin alpha 1.
    Bistoni F; Marconi P; Frati L; Bonmassar E; Garaci E
    Infect Immun; 1982 May; 36(2):609-14. PubMed ID: 7085074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.